Luigi GnudiUnit for Metabolic Medicine, Cardiovascular Division, King's College London, London, UK F1000 Faculty Member (since 22 July 2009)
Reader in Diabetes and Metabolic Medicine
Honorary Consultant in Diabetes and Endocrinology
Head, Unit for Metabolic Medicine, Cardiovascular Division
EDUCATION AND BACKGROUND:
Luigi Gnudi obtained his MD with Honours from the University of Parma (Italy) in 1988. He subsequently joined the residency programme at the School of Diabetes and Endocrinology at the University of Padua, Italy (1989-1993). During 1993-1995, he worked as a postdoctoral fellow with Prof Barbara B Kahn at Beth Israel Hospital, Harvard Medical School in Boston. In 1998 he obtained a PhD in Endocrinological Sciences from the University of Milan. He became a Fellow of both the Royal College of Physicians and the American Society of Nephrology in 2005.
Dr Gnudi joined the Unit for Metabolic Medicine (within the Department of Diabetes, Endocrinology and Internal Medicine) in 1997 as Senior Lecturer and was promoted to Reader in Diabetes and Metabolic Medicine in 2007. He became Head of the Unit for Metabolic Medicine in 2010. Dr Gnudi is an Honorary Consultant Physician in Diabetes, Endocrinology and Metabolic Medicine at Guy's and St Thomas' Hospital NHS Foundation Trust.
Dr Gnudi is subject editor for Nephrology Dialysis and Transplantation, and Journal of the American Society of Hypertension and past President of the Italian Medical Society of Great Britain. Dr Gnudi is a member of Diabetes UK, European Association for the Study of Diabetes, American Diabetes Association, American Society of Nephrology, European Diabetic Nephropathy Study Group, Physiological Society, ERA-EDTA, and also Faculty 1000.
Dr Gnudis current work is mainly concerned with the study of the mechanisms regulating vascular permeability and vascular integrity in the kidney with the object of preventing end stage renal failure. The current research programme of the Unit covers the mechanisms of glomerular injury initiated by metabolic, haemodynamic, immunological, and oxidative insults. Loss of glomerular vascular permselectivity, marked by leakage of protein into the urinary space, is a key first step in many clinical conditions which induce vessel wall injury. Proteinuria is a recognised marker of renal disease and indeed represents generalised vascular damage. Their programme utilises in vitro (cell culture), ex vivo (kidney biopsies, peripheral circulating progenitor endothelial cells), and in vivo (animal model of proteinuria, transgenics) research approaches, and provides an ideal setting for integrated research.
Viewing Article Recommendations by Faculty Members requires a subscription.
If you believe you should be able to view this content, contact us at firstname.lastname@example.org.
Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetesF1000 Medicine Reports 2010 2:(18) (15 Mar 2010)
Luigi Gnudi has been added to your "Faculty I'm Following" page in MyF1000
Follow/Unfollow any Faculty via their recommendations, biography pages, or MyF1000